Tolterodine — $0 on Listed Strengths

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Overactive Bladder

• Mirabegron
• Oxybutynin
• Solifenacin

Also listed for Overactive Bladder / Urge Incontinence

• Oxybutynin 5 mg tabs
• Solifenacin 5/10 mg tabs

Other medications in Urology

• Vardenafil
• Vibegron
• Alfuzosin
• Avanafil
• Bethanechol
• Ciprofloxacin (UTI)
• Desmopressin Nasal
• Doxazosin

About Tolterodine

Dealing with overactive bladder (OAB) can be a daily challenge, but medications like tolterodine offer a path to relief. This widely used prescription helps manage uncomfortable symptoms, improving quality of life. The good news? ### What Tolterodine Treats Tolterodine is a medication primarily prescribed to treat symptoms of an overactive bladder (OAB). OAB is a common condition characterized by a sudden, strong urge to urinate that's difficult to defer (urinary urgency), often leading to frequent urination (urinary frequency), and sometimes accidental leakage (urge incontinence). For individuals constantly planning their day around bathroom breaks or experiencing disruptive urges, tolterodine can significantly improve control and comfort, allowing for a more normal, active lifestyle. ### How Tolterodine Works Tolterodine belongs to a class of drugs known as antimuscarinics or anticholinergics. Its mechanism of action involves blocking the activity of muscarinic receptors in

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Tolterodine is approved for (FDA label)

Tolterodine tartrate extended-release capsules are an antimuscarinic indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. ( 1 ) Tolterodine tartrate extended-release capsules are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency [ see CLINICAL STUDIES ( 14 ) ].

Source: Read the full FDA label on DailyMed. Label effective date: February 9, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Tolterodine (FDA label)

Capsules: 2 mg and 4 mg ( 3 ) The 2 mg capsules are size "4", hard gelatin capsules having a green cap and green body, imprinted "1189" on the cap with white ink, containing off-white to brownish colored pellets. The 4 mg capsules are size "3", hard gelatin capsules having a blue cap and blue body, imprinted "1190" on the cap with white ink, containing off-white to brownish colored pellets.

Source: FDA prescribing information (DailyMed). Set ID: db6e0b6d-0ce5-41d7-881f-881c11f530a4. SPL document ID: de456fdd-b0a2-4b65-b926-bb9948fde276. Label effective date: February 9, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Tolterodine (FDA label)

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The most common adverse reactions (incidence ≥4% and >placebo) were dry mouth, headache, constipation, and abdominal pain. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Torrent Pharma Inc. at 1-800-912-9561 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience The efficacy and safety of tolterodine tartrate extended-release capsules was evaluated in 1,073 patients (537 assigned to tolterodine tartrate extended-release capsules; 536 assigned to placebo) who were treated with 2, 4, 6, or 8 mg/day for up to 15 months.

Source: FDA prescribing information (DailyMed). Set ID: db6e0b6d-0ce5-41d7-881f-881c11f530a4. SPL document ID: de456fdd-b0a2-4b65-b926-bb9948fde276. Label effective date: February 9, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Tolterodine (FDA label)

Tolterodine tartrate extended-release capsules are contraindicated in patients with urinary retention, gastric retention, or uncontrolled narrow-angle glaucoma. Tolterodine tartrate extended-release capsules are also contraindicated in patients with known hypersensitivity to the drug or its ingredients, or to fesoterodine fumarate extended-release tablets which, like tolterodine tartrate extended-release capsules, are metabolized to 5-hydroxymethyl tolterodine. ( 4 ) Tolterodine tartrate extended-release capsules are contraindicated in patients with urinary retention, gastric retention, or uncontrolled narrow-angle glaucoma. Tolterodine tartrate extended-release capsules are also contraindicated in patients with known hypersensitivity to the drug or its ingredients, or to fesoterodine fumarate extended-release tablets which, like tolterodine tartrate extended-release capsules, are metabolized to 5-hydroxymethyl tolterodine [ see WARNINGS AND PRECAUTIONS ( 5.2 ), ( 5.3 ), ( 5.4 ) ] .

Source: FDA prescribing information (DailyMed). Set ID: db6e0b6d-0ce5-41d7-881f-881c11f530a4. SPL document ID: de456fdd-b0a2-4b65-b926-bb9948fde276. Label effective date: February 9, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Tolterodine (FDA label)

Anaphylaxis and angioedema requiring hospitalization and emergency medical treatment have occurred with the first or subsequent doses of tolterodine tartrate extended-release capsules. ( 5.1 ) Urinary Retention: use caution in patients with clinically significant bladder outflow obstruction because of the risk of urinary retention. ( 5.2 ) Gastrointestinal Disorders: use caution in patients with gastrointestinal obstructive disorders or decreased gastrointestinal motility because of the risk of gastric retention. ( 5.3 ) Controlled Narrow-Angle Glaucoma: use caution in patients being treated for narrow-angle glaucoma. ( 5.4 ) Central Nervous System Effects: Somnolence has been reported with tolterodine tartrate extended-release capsules.

Source: FDA prescribing information (DailyMed). Set ID: db6e0b6d-0ce5-41d7-881f-881c11f530a4. SPL document ID: de456fdd-b0a2-4b65-b926-bb9948fde276. Label effective date: February 9, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Tolterodine (FDA label)

Potent CYP3A4 Inhibitors: Coadministration may increase systemic exposure to tolterodine tartrate extended-release capsules. Reduce tolterodine tartrate extended-release capsules dose to 2 mg once daily. ( 7.2 ) Other Anticholinergics (antimuscarinics): Concomitant use with other anticholinergic agents may increase the frequency and/or severity of dry mouth, constipation, blurred vision, and other anticholinergic pharmacological effects. (7.6 ) 7.1 Potent CYP2D6 Inhibitors Fluoxetine, a potent inhibitor of CYP2D6 activity, significantly inhibited the metabolism of tolterodine immediate release in CYP2D6 extensive metabolizers, resulting in a 4.8-fold increase in tolterodine AUC. There was a 52% decrease in C max and a 20% decrease in AUC of 5-hydroxymethyl tolterodine (5-HMT), the pharmacologically active metabolite of tolterodine [ see CLINICAL PHARMACOLOGY ( 12.1 ) ]. The sums of unbound serum concentrations of tolterodine and 5-HMT are only 25% higher during the interaction.

Source: FDA prescribing information (DailyMed). Set ID: db6e0b6d-0ce5-41d7-881f-881c11f530a4. SPL document ID: de456fdd-b0a2-4b65-b926-bb9948fde276. Label effective date: February 9, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.